On the analyst front, Citi and UBS both described Novo’s readout as favorable for Eli Lilly.
The Dow Jones Industrial Average is experiencing its longest losing streak since 1978, falling for nine successive trading days. This marks a significant downturn, with the index dropping roughly 3%, or...
Does this top-rated biotech stock deserve a spot in investors' portfolios before its Russell 2000 inclusion?
The Dow Jones Industrial Average has been on its worst losing streak in nearly 50 years as investors continued to rotate out of old economy names and pile into tech stocks and small-caps. The blue-chip...
It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare...
Whether you're looking for a way to beat the benchmark S&P 500 index or you just want a steady flow of passive income, dividend-paying stocks are a great way to achieve your investment goals.
Looking for reliable income in the stock market? You might want to consider the top Dogs of the Dow in December. Here's what you need to know about this trio of blue-chip stocks.
Equities continued their post-election rally after Friday’s solid November jobs report and all signs point to the rally in stocks extending into 2025
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies.
/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Despite Regeneron Pharmaceuticals’ significant underperformance relative to Nasdaq recently, Wall Street analysts remain strongly optimistic about the stock’s prospects.